子宮頸癌人類乳突病毒的病毒血症

Human Papillomavirus in Circulation of Patients with Cervical Cancer

人類乳突病毒（HPV, human papillomavirus）一向被認為是經性行為或皮膚接觸傳染，沒有病毒血症（viremia）。最近有研究認為，HPV可以在子宮頸癌患者末梢的血液、血漿、血清中偵測到。子宮頸癌HPV病毒血症的發生率差異很大，報告在11.8-65％之間，可能與使用不同診斷的技術有關。至於HPV如何進入血液循環，HPV DNA的在循環中生物學上的作用則仍不瞭解。文獻結論認為，在晚期病灶血清中HPV DNA之含量可反應出有無轉移的病灶，將來是否可以此作為子宮頸癌患者治療後的一項監測標記，值得研究者努力。

It has been widely accepted that human papillomavirus(HPVs) are not disseminated to other sites by blood, namely, there is no viremia in the course of HPV infection. However, HPV DNA can be detected in the peripheral blood mononuclear cells, sera, or plasma of patients with cervical cancer recently. Detection rates of HPV viremia differ between studies from 11.8% to 65% depending on the techniques used. The biological role of circulating DNA is still unclear. The hypothesis has been advanced that circulating tumor DNA in the serum/plasma might play a role in metastasis. The circulating HPV DNA might be a valuable marker for monitoring the therapeutic response and disease progression in cervical cancer.